Reportlinker Adds World Prostate Cancer Therapeutics Market Report

World
Prostate Cancer Therapeutics Market

http://www.reportlinker.com/p0119471/World-Prostate-Cancer-Therapeutics-Market.html

This report analyzes the worldwide markets for Prostate Cancer
Therapeutics in US$ Millions. Analytics in the report specifically
focuses on revenues generated from hormonal therapies.The report
provides separate comprehensive analytics for US, Europe, and Rest of
World. Annual forecasts are provided for each region for the period of
2006 through 2015. The report profiles 138 companies including many key
and niche players worldwide such as Abbott Laboratories, AEterna Zentaris
Inc., ALZA Corporation, Amgen Inc., AstraZeneca PLC., Medimmune, LLC,
Bristol-Myers Squibb Company, Cell Genesys Inc., Dendreon Corporation,
EUSA Pharma, (USA) Inc., F. Hoffmann-La Roche Ltd., Genentech Inc.,
GlaxoSmithKline Plc., Immunomedics, Inc., Indevus Pharmaceuticals Inc.,
Novartis AG, OSI Pharmaceuticals, Inc., Paladin Labs Inc., Pfizer Inc.,
Progenics Pharmaceuticals, Inc., Sanofi-Aventis SA, Spectrum
Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. Market
data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported
select online sources.

PROSTATE CANCER THERAPEUTICS A GLOBAL STRATEGIC BUSINESS REPORT MCP-1747

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data
Interpretation & Reporting Level I-2 Product Definitions and Scope of
Study I-3 Hormonal Therapy I-3 Radiation Therapy I-4 Chemotherapy I-4
Surgical Procedures I-4 Other Treatment Options I-4

II. EXECUTIVE SUMMARY

1. Industry Overview II-1 A Prelude II-1 New Products to Bolster Sales
of Prostate Cancer Therapeutics II-1 Key Prostate Cancer Drugs &
Companies II-2 Hormone Therapies to Dominate Global Prostate Cancer
Therapeutics Market II-2

Table 1: Sales of FDA Approved Prostate Cancer Hormonal Therapy Drugs in
the US for 2007 (includes corresponding Graph/Chart) II-2 Select
Prostate Cancer Hormonal Therapy Drugs with Year of FDA Approval II-3
Targeted Therapy - The New Frontier of Cancer Treatment II-3
Radiotherapy - Gaining Prominence II-3 Innovations in Drug Delivery: A
Key Factor in Product Differentiation II-4 New Therapies Appear Over the
Horizon II-4 New Generation Prostate Cancer Drugs and Their Area of Use
II-4 Small Cap Companies: A Target of Private Capital Financing II-5
Drugs (that are both available and under pipeline) Developed by the
Three Small-Cap Companies II-5 Minimally Invasive Devices Likely to Get
Good Reception in Emerging Markets II-5 Awareness Drives European
Prostate Cancer Therapeutics Market II-6 Growth Drivers II-6 Rise in
Prostate Cancer Incidences & Access to Modern Therapeutics Foster Growth
II-6

Table 2: New Incidences of Prostate Cancer (in '000) Worldwide for the
years 2004 through 2007 (includes corresponding Graph/Chart) II-6

Table 3: New Cancer Cases Diagnosed in the US in 2007: Percentage Share
by Leading Cancer Sites (includes corresponding Graph/Chart) II-7
Demographics & Lifestyles Raise the Risk of Prostate Cancer II-7

Table 4: Probability of Developing Invasive Prostate Cancer by Age Group
in the US (includes corresponding Graph/Chart) II-7

Table 5: Male Population by Age Group in the US for the year 2007
(includes corresponding Graph/Chart) II-8 Select General Risk Factors
and their Relative Risk Rate in Prostate Cancer II-8 Unmet Needs Leave
Scope for Further Research and Development II-8 Supportive Cancer Drugs
Contribute to Growth II-8 Select FDA Approved Drugs for Palliative
Treatment of Advanced Prostate Cancer II-9 Improved Screening, Diagnosis
& Patient Survival Rates Trigger Growth II-9

Table 6: Five-Year Prostate Cancer Survival Rate in the US by Race,
1975-2002 (includes corresponding Graph/Chart) II-9

Table 7: Five-Year Cancer Survival Rate Among US Males by Type -
Prostate and Testis (1996-2002) (includes corresponding Graph/Chart)
II-10

Table 8: Five-Year Cancer Survival Rate (%) in the US by Race, 1996-2003
(includes corresponding Graph/Chart) II-10 Molecular Imaging of Cancer:
Critical in Improving Patient Outcomes II-11 Growth Restraints II-11
Limited Tumor Specificity and Toxicity II-11 Complicated Treatment
Protocols: A Major Stumbling Block in Patient Compliance II-11 Multiple
Drug Resistance II-12 Stringent Regulations Delay Market Approval II-12
Ongoing Clinical Trials in Hormone Refractory Prostate Cancer II-12
Challenges Encountered in Clinical Trials II-12 Notable Prostate Cancer
Drug Failures in Phase III Development II-13 High Development Costs
Retracts Manufacturers in Developing Countries II-13

2. Clinical Trials II-14 Drugs in Pipeline II-14 Select Prostate Cancer
Drugs/Compounds in Pipeline II-14 Select Prostate Cancer Drugs Under
Phase II/III Trials by Leading Companies II-15 Drugs in Pre-Clinical
Stage II-16 Select Prostate Cancer Drugs/Compounds in Pre-Clinical Stage
II-16 Commercially Available Drugs II-16 Select Prostate Cancer Drugs
(Commercially Available) by Leading Companies II-16

3. Product Overview II-17 Cancer: A Major Health Crises in the Modern
World II-17

Table 9: Mortality Rate in the US for the Year 2005 by Ailment - Heart
Diseases, Cancer, Cerebrovascular Diseases, Chronic Lower Respiratory
Diseases, and Accidents (Unintentional Injuries) (includes corresponding
Graph/Chart) II-17

Table 10: Mortality Rate in the US for the Year 2005: Percentage
Breakdown by Cause of Death -Heart Diseases, Cancer, Cerebrovascular
diseases, Chronic lower respiratory diseases, Accidents (unintentional
injuries), and Others (includes corresponding Graph/Chart) II-17

Table 11: Cancer Death Rates in the US (2007): Percentage Breakdown by
Cancer Type - Lung & Bronchus, Prostate, Colon & Rectum, Pancreas,
Leukemia, and Others (includes corresponding Graph/Chart) II-18

Table 12: Comparison of Mortality Among African Americans and Whites by
Cancer Type in the US, 2000- 2004 (includes corresponding Graph/Chart)
II-18 Prostate - Structure II-18 Pituitary Gland II-19 Testes II-19
Prostate Cancer - A Primer II-20 Key Facts to Gaze at II-20

Table 13: Lifetime Probability of Developing Cancer (in Men) by Type in
the US, 2002-2004 II-20

Table 14: New Incidences of Prostate Cancer (in '000) Worldwide for the
years 2007 and 2008 (includes corresponding Graph/Chart) II-21

Table 15: Mortality Due to Prostate Cancer (in '000) Worldwide for the
Years 2007 and 2008 (includes corresponding Graph/Chart) II-22

Table 16: Male Population (in Million) for the Year 2007 for Select
Regions (includes corresponding Graph/Chart) II-23 Screening/Detection
of Prostate Cancer II-24 Digital Rectal Exam (DRE) II-24 Transrectal
Ultrasound (TRUS) II-24 PSA Blood Test II-24 Strategies to Enhance
Screening/Detection of Prostate Cancer II-24 Improved PSA Testing II-25
Total PSA, Free PSA and PSA-Alpha-1-Protease Inhibitor Levels II-25
Insulin-like Growth Factor (IGF-1) and Intact IGF- Binding Protien-3
(IGF-BP3) II-25 GSTP1 Methylation Levels and Prostate Cancer Diagnosis
II-25 Microbubble Ultrasound II-26 Staging of Prostate Cancer II-26
Gleason Score II-27 Gleason Score and Grading of Prostate Cancer II-27
TNM Staging II-27 T-Staging Analysis of Prostate Cancer II-27 Genetic &
Non-Genetic Factors II-28 Hereditary or Genetic Factors II-28
Non-Genetic or Environmental Factors II-28

Table 17: Prostate Cancer Incidence/Mortality Rate by Race & Ethnicity
in US, 1999-2003 (includes corresponding Graph/Chart) II-29 Prevention
of Cancer II-30 Role of Diet in Prostate Cancer II-30

4. Treatment Options for Prostate Cancer II-32 Hormonal Therapy II-32
Medical Hormone Therapy II-32 LHRH Analogs II-33 Dose of LHRH Agonists
for Advance Prostate Carcinoma Treatment II-33 Anti-Androgens II-34
Leading Non-Steroidal Anti-androgen Hormonal Therapy Drugs for Prostate
Cancer II-34 Anti-Androgen Monotherapy II-34 Orchiectomy II-35 Side
Effects of Orchiectomy II-35 Time to Start Hormonal Therapy II-35
Strategies to Enhance Hormonal Treatment II-36 Combination Therapy II-36
Intermittent Therapy II-36 Radiation Therapy II-36 Brachytherapy II-36
Treatment Procedure II-37 Benefits of Brachytherapy II-38 Drawbacks of
Brachytherapy II-38 High Dose Rate (HDR) Brachytherapy II-39 External
Beam Radiation Therapy (EBRT) II-39 Side Effects of Radiotherapy II-39
Strategies to Enhance Radiation Treatment II-39 New Radiation Techniques
II-39 Whole Pelvic Radiation Therapy (WPRT) II-40 New Radiation Devices
II-40 Chemotherapy II-40 Risks Associated with Chemotherapy II-41
Surgical Procedures for Prostate Cancer II-41 Transurethral Resection of
the Prostate (TURP) II-41 Prostatectomy and Lymph Node Dissection II-42
Radical Prostatectomy II-42 Cryosurgery II-43 Advantages of Cryosurgery
II-43 Disadvantages of Cryosurgery II-43 Other Treatment Options II-43
Intensity Modulated Radiation Therapy (IMRT) II-43 Benefits of IMRT
II-44 Drawbacks of IMRT II-44 Androgen Deprivation Therapy (ADT) II-44
High Dose Radiation (HDR) Monotherapy II-45 Drawbacks of HRD II-45
Choosing the Optimal Treatment Method II-45 Recurrent Prostate Cancer
II-46 Recurrent Prostate Cancer Subsequent to Surgery II-46 Recurrent
Prostate Cancer Subsequent to Radiation Therapy II-47 Hormone-Refractory
Prostate Cancer (HRPC) II-47 Select Drugs in Advanced Development Stage
for Hormone- Refractory Prostate Cancer II-47 Chemotherapy II-47
TCaxotere(R) (Docetaxel) II-48 Bone Complication Treatments II-48
Bisphosphonate Drugs II-48 Doxazosin, a Cytotoxic Drug for Prostate
Cancer II-49 Radiation Therapy II-49 Strategies to Enhance Recurrent
Prostate Cancer Treatment II-49 Chemotherapy - New Regimens II-49 Phase
I Clinical Trials II-50 Combination Therapy II-50 Gene Therapy II-50
Targeted Therapy II-50 Selective Endothelia A Receptor Antagonist -
(SERA(TM)) II-51 Other Select Targeted Therapies II-52 Tyrosine Kinase
Inhibitors II-52 Anti-Angiogenic Drugs II-52 Monoclonal Antibodies II-52
Vaccines II-52 Radioactive Monoclonal Antibodies II-52

5. Drug Approvals and Clinical Studies II-53 Debiopharm Unveils Results
of Phase III Study of Trelstar in Prostate Cancer Treatment II-53 Algeta
to Start Clinical Study of Alpharadin in HRPC II-53 Ferring Receives FDA
Approval for Degarelix in Prostate Cancer II-53 Isis and OncoGenex
Reveals Positive results of OGX- 011 Molecule in HRPC II-53 Antisoma
Completes Phase 2 Study of ASA404 in Prostate Cancer II-53 Cougar
Conducts Phase I/II Clinical Trials on CB7630 in Patients with Prostate
Cancer II-54 Ambrilia Unveils Results of PCK3145 in Patients with
Metastatic Prostate Cancer II-54 Peregrine Pharmaceuticals Reveals
Pre-Clinical Data on Bavituximab in Prostate Cancer II-54 Cell Genesys
Reveals Data of GVAX Immunotherapy for Treatment of Prostate Cancer
II-54 Bioponic Phytoceuticals Unveils Pre-Clinical Data on Curecumin(TM)
for Prostate Cancer II-55 New Study Reveals Cough Medicine - Noscapine
to be Effective in Prostate Cancer II-55 Fosamax(R) Found Effective in
Preventing Bone Loss in Prostate Cancer Patients II-55 Genta Unveils
Results of Phase II Clinical Trial of Genasense(R) in Prostate Cancer
II-55 Cell Therapeutics Reveals Phase 2 Clinical Trial Results of
XYOTAX(TM) in Androgen Independent Prostate Cancer Patients II-56
Sanofi-Aventis' Taxotere(R) Enhances Survival in Metastatic Prostate
Cancer Patients II-56 NCI Initiates Phase 2 Clinical Trial of Cytogen's
QUADRAMET for HRPC II-56 Cleveland BioLabs to Initiate Phase II Clinical
Trial for Curaxin in HRPC II-57 NeoRx Begins Clinical Study for
Picoplatin in Prostate Cancer II-57 Novacea Starts Phase III Clinical
Trial for Treatment of Prostate Cancer II-57 Next Pharmaceuticals'
Supplement Nexrutine Help Prevent Prostate Cancer II-57 Antisoma Reveals
Results from AS1404 Phase II Clinical Trial in HRPC II-57 Marshall
Edwards Conducts Study on Phenoxodiol in Prostate Cancer II-58
Combination of Provenge(R) and Taxotere(R) Offer Better Results for HRPC
Patients II-58 Ambrilia Reveals Results of PSP-94 Immunoassay Study for
Cancer Therapy II-58 University of California's Analyses Support
Dendreon's Active Cellular Immunotherapy II-59 Spectrum Announces
Positive Outcome of Satraplatin Trial on HRPC Patients II-59 Panacea
Pharmaceuticals Identifies Blood Protein for Early Prostate Cancer
Detection II-60 Active Biotech Reveals Results of TASQ Phase I Study for
Prostate Cancer II-61 Positive Results of Combined Hormone and Radiation
Therapies in Locally Advanced Prostate Cancer II-61 Positive Results
from Use of IMRT in Localized Prostate Cancer II-61 Balanced Intake of
Omega-6 and Omega-3 Fatty Acids Found to Reduce Prostate Cancer Growth
II-62 Sanofi's Taxotere Gains Approval from Nice of UK for Use in
Late-Stage Prostate Cancer II-62 Protox Gains Clearance from FDA to
Conduct Phase I Trial of PRX302 II-63 AEterna Zentaris's Ozarelix Phase
II Trial Shows Positive Results II-63 Biomira Announces Results of
Stimuvax Phase 2 Clinical Study II-64 Cytogen Receives FDA Clearance for
CYT-500 IND Application II-64 US Researchers Unveils New Therapeutic
Cancer Vaccine For Metastatic Prostate Cancer II-64 PNNL and IsoRay
Develops Cesium-131 Seed for Treatment of Prostate Cancer II-65

6. Product Innovations/Introductions II-66 Speciality European Pharma
Introduces Plenaxis II-66 Actavis Unveils Bicalutamide Tablets for
Prostate Cancer in the European Markets II-66 Artemis to Introduce IGRT
II-66 Immunomedics Introduces Immunotoxin for Treatment of Prostate and
Lung Cancer II-66 Barr Unveils Generic Version of Proscar(R) Tablets II-67
IRX Therapeutics to Develop Vaccine for Prostate Cancer II-67 Actavis
Introduces New Generic Drugs in Europe II-67 Robot-Assisted Radical
Prostatectomy for Treatment of Prostate Cancer II-67

7. Recent Industry Activity II-68 Sanofi-Aventis Secures Approval of
Japanese Health Ministry for Taxotere(R) Injection II-68 Schering-Plough
Terminates Collaboration with Novacea II-68 Takeda Terminates JV Deal,
Merges its Subsidiaries II-68 Aureon Laboratories and Pfizer Announce
Research Partnership II-68 Celera Enters into Licensing Agreement with
Merck II-69 Celera Announces Demerger from Applera Corporation II-69 GPC
Biotech and Celgene Terminate Agreement for Satraplatin II-70 EUSA
Acquires Cytogen Corporation II-70 Eisai Acquires MGI Pharma II-70 BN
ImmunoTherapeutics Enters into a Scientific Partnership with NCI II-70
Morphotek(R) Enters into Licensing Agreement with NCI II-71 ValiRx
Acquires Exclusive Evaluation License from CRT for New Prostate Cancer
Compound II-71 Cell Genesys Forms Global Alliance with Takeda on GVAX
Immunotherapy Development for Prostate Cancer II-71 Sirnaomics Extends
Partnership with GRL to Develop Multi- Targeted RNAi Therapeutic
Products II-72 Aureon and Pfizer to Collaborate on New Stage of Research
Project II-72 CancerPartners UK Collaborates with Spire Healthcare II-72
Cougar Biotech Enters into an Agreement with US FDA II-73 Scottish
Scientists Receives Contract from Cancer Research UK II-73 ValiRx
Collaborates with University of Surrey on Prostate Cancer Diagnostics
II-73 ValiRx Subsidiary Extends Collaboration with Cancer Research
Technology II-73 MacroArray Partners with Abbott on PCADM-1 Test for
Prostate Cancer II-74 Novacea Enters into Agreement with Schering-Plough
II-74 Bayer to Stop Sale of Viadur - A Drug for Prostate Cancer II-74
Sagemark Embarks on Radiation Therapy Venture II-75 RTS Concludes
Californian Radiation Therapy Center Acquisition II-75 Radiation Therapy
Takes Over a North Carolina Treatment Center II-75 DRAXIMAGE and Med
Discovery Enter into Research Collaboration II-75 Core Oncology
Completes Acquisition of Coloplast's Brachytherapy Business II-76
Novacea Licenses Asenstar Prostate Cancer Drug to Schering-Plough II-76
Bentley Receives Approval for Generic Version of Casodex II-76 GSK
Acquires Praecis Pharmaceuticals II-77 Samaritan Acquires Metastatin
Pharma II-77 Champions Biotechnology Acquires Patent Rights for
Potential Cancer Treatments II-77 GPC Biotech Submits NDA for Treatment
of Prostate Cancer II-77 MedMira Inks Agreement to Take Over Rights of a
New Marker Technology II-78 Cell Genesys's GVAX Prostate
Cancer-Treatment Attains FDA's Fast Track Tag II-78 Envisioneering
Medical Enters into Agreement with BrachySciences II-78 Signet Enters
into Agreement with AsymmetRx to Distribute ' Prostate-63' Tests II-79
Mylan Pharmaceuticals Obtains FDA Approval for Finasteride's ANDA II-79
AEterna Zentaris Enters into Agreement with Nippon Kayaku II-79 Progenics
Pharmaceuticals Broadens Association with Seattle Genetics II-80
Diosynth and Dendreon Sign Multi-Year Commercial Supply Deal II-80
Genstar Capital Completes Acquisition of OnCure II-80 Generex
Biotechnology Expands Antigen Express Cancer Trials II-80 Progenics
Pharmaceuticals Acquires PSMA Development Company II-81 Schweizerhall
Acquires Novosis II-81 Misonix Expands into France with Sonablate(R) 500
II-81 Indevus Enters into Agreement to Takeover Valera II-82 Oncobionic
Receives FDA Clearance for Cancer Treatment Technology II-82 Misonix
Expands HIFU Business in Europe by Entering into Spain II-82 Altana
Divests Entire Stake in GPC Biotech II-83 Ipsen Enters into Partnership
with GTx to Develop and Market Acapodene in Europe II-83 Egenix and
Proteome Systems Collaborate to Develop Prostate Cancer Test Using Semen
II-83 Valera and Spepharm Partner to Market Vantas, and Supprelin-LA
II-84 SurModics and AbbeyMoor Collaborate to Develop Products to Treat
Prostate Diseases II-84 Dendreon Constructs Manufacturing Facility in
New Jersey II-84 MediGene Introduces Prostate Cancer Drug in Italian
Market II-85 Gen-Probe Introduces Innovative Test for Prostate Cancer in
Europe II-85 DRL Introduces Generic Version of Proscar II-85 Ferring
Partners with Astellas on Degarelix License for Prostate Cancer
Treatment II-85 Protox Acquires PRX321 Cancer Program from US Public
Health Service and Neurocrine II-86 Astex Collaborates with CRT and
Newcastle University for New Drug Discovery II-86 Miraculins and Duke
University Enter into Collaboration II-86 Bayer Receives Rights to
Prostate Cancer and Transplantation Drug Test from Abbott II-86 Encorium
Group Signs Contract with Global Biopharmaceutical Company II-86 Paladin
Signs an Agreement with Watson for Supply and Sale of Trelstar(R) II-87
BioWa Obtains License for Anti-FGF8 Antibody from Kyowa Hakko II-87
OncoGenex and Isis Pharmaceuticals Expand Partnership II-87 Caprion and
AstraZ eneca Enter into Collaboration II-88 Innovate Oncology and
Prostagenics Enter into Capridine- Beta Development Agreement II-88
Protein Design Labs Sublicenses Antibody-Drug Conjugates Development
Rights to Genentech II-88 National Cancer Institute Enters into
Agreement with Illumina II-89 Sosei Seeks Marketing Rights for Prostate
Cancer Drug in Japan II-89

8. Focus on Select Global Players II-90 Abbott Laboratories (USA) II-90
AEterna Zentaris Inc. II-90 ALZA Corporation (USA) II-90 Amgen Inc. (USA)
II-91 AstraZeneca PLC (UK) II-91 Medimmune, LLC (USA) II-92
Bristol-Myers Squibb Company (USA) II-92 Cell Genesys Inc. (USA) II-92
Dendreon Corporation (USA) II-93 EUSA Pharma, (USA) Inc. (USA) II-93 F.
Hoffmann-La Roche Ltd. (Switzerland) II-94 Genentech Inc. (USA) II-94
GlaxoSmithKline Plc (UK) II-95 Immunomedics, Inc. (USA) II-95 Indevus
Pharmaceuticals Inc. (USA) II-95 Novartis AG (Switzerland) II-96 OSI
Pharmaceuticals, Inc. (USA) II-96 Paladin Labs Inc. (Canada) II-97
Pfizer Inc. (USA) II-97 Progenics Pharmaceuticals, Inc. (USA) II-97
Sanofi-Aventis SA (France) II-98 Spectrum Pharmaceuticals, Inc. (USA)
II-98 Takeda Pharmaceutical Company Limited (Japan) II-98

9. Global Market Perspective II-100

Table 18: World Recent Past, Current & Future Analysis for Prostate
Cancer Therapeutics by Geographic Region/ Country - US, Europe, and Rest
of World Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
II-100

Table 19: World 10-Year Perspective for Prostate Cancer Therapeutics by
Geographic Region/Country - Percentage Breakdown of Dollar Sales for US,
Europe, and Rest of World Markets for Years 2006, 2009 & 2015 (includes
corresponding Graph/Chart) II-101

III. MARKET

1. The United States III-1 A.Market Analysis III-1 Overview III-1 A
Surging US Prostate Cancer Therapeutics Market III-1

Table 20: Probability of Developing Invasive Prostate Cancer by Age
Group in the US (includes corresponding Graph/Chart) III-1

Table 21: Male Population by Age Group in the US for the Year 2007
(includes corresponding Graph/Chart) III-2 Cost of Cancer Drugs - A
Major Concern in the US III-2 Market Accelerators III-2 Market
Challenges III-3 Market Inhibitors III-3

Table 22: Sales of FDA Approved Prostate Cancer Hormonal Therapy Drugs
in the US for 2007 (includes corresponding Graph/Chart) III-3 Current
and Future Analysis III-3 Key Statistics III-4

Table 23: Mortality Rate in the US for the Year 2005 by Ailment - Heart
Diseases, Cancer, Cerebrovascular Diseases, Chronic Lower Respiratory
Diseases, and Accidents (Unintentional Injuries) (includes corresponding
Graph/Chart) III-4

Table 24: Mortality Rate in the US for the Year 2005: Percentage
Breakdown by Cause of Death -Heart Diseases, Cancer, Cerebrovascular
diseases, Chronic lower respiratory diseases, Accidents (unintentional
injuries), and Others (includes corresponding Graph/Chart) III-4

Table 25: Cancer Death Rates in the US (2007): Percentage Breakdown by
Cancer Type - Lung & Bronchus, Prostate, Colon & Rectum, Pancreas,
Leukemia, and Others (includes corresponding Graph/Chart) III-4

Table 26: New Cancer Cases Diagnosed in the US in 2007: Percentage Share
by Leading Cancer Sites (includes corresponding Graph/Chart) III-5

Table 27: New Cases of Prostate Cancer Diagnosed in the US: Breakdown by
Leading States for the Years 2007 and 2008 (includes corresponding
Graph/Chart) III-5

Table 28: Mortality Due to Prostate Cancer in the US: Breakdown by
Leading States for the Years 2007 and 2008 (includes corresponding
Graph/Chart) III-6

Table 29: Lifetime Probability of Developing Cancer (in Men) by Type in
the US, 2002-2004 III-6

Table 30: Comparison of Mortality Among African Americans and Whites by
Cancer Type in the US, 2000-2004 (includes corresponding Graph/Chart)
III-7

Table 31: Five-Year Prostate Cancer Survival Rate in the US by Race,
1975-2002 (includes corresponding Graph/Chart) III-7

Table 32: Five-Year Cancer Survival Rate Among US Males by Type -
Prostate and Testis (1996-2002) (includes corresponding Graph/Chart)
III-8

Table 33: Five-Year Cancer Survival Rate (%) in the US by Race,
1996-2003 (includes corresponding Graph/Chart) III-8

Table 34: Prostate Cancer Incidence/Mortality Rate by Race & Ethnicity
in US, 1999-2003 (includes corresponding Graph/Chart) III-9 Clinical
Trials III-9 Product Launches III-19 Strategic Corporate Developments
III-19 Select Players III-32 B.Market Analytics III-41

Table 35: US Recent Past, Current & Future Analysis for Prostate Cancer
Therapeutics Market with Annual Sales Figures in US$ Million for Years
2006 through 2015 (includes corresponding Graph/Chart) III-41

2. Europe III-42 A.Market Analysis III-42 Overview III-42 Awareness
Drives European Prostate Cancer Therapeutics Market III-42

Table 36: New Cases of Prostate Cancer Diagnosed in Europe: Breakdown by
Region/Country for the Years 2007 and 2008 (In '000) (includes
corresponding Graph/Chart) III-42

Table 37: Mortality Due to Prostate Cancer in Europe: Breakdown by
Region/ Country for the Years 2007 and 2008 (In '000) (includes
corresponding Graph/Chart) III-43 Current and Future Analysis III-43
Clinical Trial III-43 Product Launches III-44 Strategic Corporate
Developments III-44 B.Market Analytics III-46

Table 38: European Recent Past, Current & Future Analysis for Prostate
Cancer Therapeutics by Geographic Region/Country - France, Germany,
Italy, United Kingdom, Spain, and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years 2006 through
2015 (includes corresponding Graph/Chart) III-46

Table 39: European 10-Year Perspective for Prostate Cancer Therapeutics
by Geographic Region/Country - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, United Kingdom, Spain, and Rest of Europe
Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
III-47

2a. France III-48 A.Market Analysis III-48 Overview III-48 Anti-Androgen
and LHRH Analogs Drive the French Market III-48 Current and Future
Analysis III-48 Clinical Trials III-48 Strategic Corporate Developments
III-49 Select Players III-50 B.Market Analytics III-51

Table 40: French Recent Past, Current & Future Analysis for Prostate
Cancer Therapeutics Market with Annual Sales Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-51

2b. Germany III-52 A.Market Analysis III-52 Current and Future Analysis
III-52 Product Launch III-52 Strategic Corporate Developments III-52 GPC
Biotech AG - A Major Player III-54 B.Market Analytics III-54

Table 41: German Recent Past, Current & Future Analysis for Prostate
Cancer Therapeutics Market with Annual Sales Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-54

2c. Italy III-55 A.Market Analysis III-55 Italian Prostate Cancer
Therapeutics Market - An Overview III-55 Current and Future Analysis
III-55 Clinical Trial III-55 Strategic Corporate Development III-55
B.Market Analytics III-56

Table 42: Italian Recent Past, Current & Future Analysis for Prostate
Cancer Therapeutics Market with Annual Sales Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-56

2d. The United Kingdom III-57 A.Market Analysis III-57 Overview III-57
LHRH Analogs - The Market Driver III-57 Current and Future Analysis
III-57 Clinical Trials III-57 Product Launch III-58 Strategic Corporate
Developments III-58 Select Players III-60 B.Market Analytics III-62

Table 43: UK Recent Past, Current & Future Analysis for Prostate Cancer
Therapeutics Market with Annual Sales Figures in US$ Million for Years
2006 through 2015 (includes corresponding Graph/Chart) III-62

2e. Spain III-63 A.Market Analysis III-63 Overview III-63 Spanish
Prostate Cancer Therapeutics Market - On a Roll III-63 Current and
Future Analysis III-63 Strategic Corporate Developments III-63 B.Market
Analytics III-64

Table 44: Spanish Recent Past, Current & Future Analysis for Prostate
Cancer Therapeutics Market with Annual Sales Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-64

2f. Rest of Europe III-65 A.Market Analysis III-65 Current and Future
Analysis III-65 Clinical Trials III-65 Strategic Corporate Development
III-65 Select Players III-66 B.Market Analytics III-67

Table 45: Rest of Europe Recent Past, Current & Future Analysis for
Prostate Cancer Therapeutics Market with Annual Sales Figures in US$
Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
III-67

3. Rest of World III-68 A.Market Analysis III-68 Current and Future
Analysis III-68 A Peek into Canadian Market III-68

Table 46: New Cases of Prostate Cancer Diagnosed in Canada (2008):
Breakdown by Leading Province (includes corresponding Graph/Chart) III-68

Table 47: Mortality Due to Prostate Cancer Diagnosed in Canada (2008):
Breakdown by Leading Province (includes corresponding Graph/Chart) III-68

Table 48: Prostate Cancer Market in Canada (2008): New Cases and Deaths
Due to Prostate Cancer by Age Group III-69 Ambrilia Unveils Results of
PCK3145 in Patients with Metastatic Prostate Cancer III-69 Ambrilia
Reveals Results of PSP-94 Immunoassay Study for Cancer Therapy III-69
Select Canadian Players III-70 A Glance into Other Select Markets III-71
Minimally Invasive Devices Likely to Get Good Reception in Emerging
Markets III-71 Cancer Market in Asia III-72 Australia III-72 India
III-72 Japan III-72 Malaysia III-73

Table 49: New Cases of Prostate Cancer Diagnosed in Asia-Pacific:
Breakdown by Region/Country for the Years 2007 and 2008 (includes
corresponding Graph/Chart) III-73

Table 50: Mortality Due to Prostate Cancer in Asia-Pacific: Breakdown by
Region/ Country for the Years 2007 and 2008 (includes corresponding
Graph/Chart) III-73 Cancer Market in Latin America III-74 Brazil III-74
Mexico III-74 Argentina III-74

Table 51: New Cases of Prostate Cancer Diagnosed in Latin America:
Breakdown by Region/Country for the Years 2007 and 2008 (includes
corresponding Graph/Chart) III-74

Table 52: Mortality Due to Prostate Cancer in Latin America: Breakdown
by Region/ Country for the Years 2007 and 2008 (includes corresponding
Graph/Chart) III-75 Clinical Trial III-75 Product Launch III-75
Strategic Corporate Developments III-76 Select Players III-78 B.Market
Analytics III-79

Table 53: Rest of World Recent Past, Current & Future Analysis for
Prostate Cancer Therapeutics Market with Annual Sales Figures in US$
Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
III-79

IV. COMPETITIVE LANDSCAPE

To order this report: World
Prostate Cancer Therapeutics Market

http://www.reportlinker.com/p0119471/World-Prostate-Cancer-Therapeutics-Market.html

More market research reports here!

SOURCE: ReportLinker

Reportlinker 
Nicolas: nbo@reportlinker.com 
US: (805)-652-2626 
Intl: +1 805-652-2626

For full details on (CTHP) CTHP. (CTHP) has Short Term PowerRatings at TradingMarkets. Details on (CTHP) Short Term PowerRatings is available at This Link.